TAF4B

Across TCGA pan-cancer cohorts, TAF4B Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated TAF4B data layer compared with 28 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher TAF4B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TAF4B expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

KIRC, BRCA, and UCEC are the cancer types where TAF4B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	OS	Median	All	0.134	0.811	<.001	30	view →
BRCA	OS	Median	II,III,IV	0.350	0.913	<.001	23	view →
UCEC	DFS	Median	All	1.000	0.828	.010	22	view →
OV	OS	Median	All	0.361	0.842	.004	18	view →
SCLC	OS	Median	II,III,IV	0.082	0.648	<.001	18	view →
KIRP	OS	Median	All	0.111	0.702	.001	12	view →
GBM	DFS	Median	All	0.048	0.257	.001	6	view →
LIHC	DFS	Median	II,III,IV	0.044	0.427	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

TAF4B–KIRC (OS)

Open the KIRC breakdown →